Allowed patent application claims method for purifying actinium-225 NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming the purification of actinium-225 (Ac-225), the alpha-emitting radioisotope used in Actimab-A. Actimab-A is currently in a Phase 2 clinical trial in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium said, "We are pleased to receive this Notice of Allowance from the USPTO. Thanks in large part to our intellectual property and know how, Actinium is a leader in the radioimmunotherapy field. We will continue to strengthen this leadership position with additional intellectual property and know how as we simultaneously progress Iomab-B, Actimab-A and future drug candidates through clinical trials." Actinium recently reported results from a Phase 1 trial of Actimab-A, which will be presented in a poster session on December 5, 2016 at the 58 th Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, California from December 3 - 6, 2016. The Phase 1 trial treated 18 patients (median age, 77 years; range, 68-87 years) in a dose escalation study with doses ranging from 0.5 - 2.0 µCi/kg/fraction with a 28% response rate observed across the 4 dosing cohorts. Peripheral blast burden was identified as a strong predictor of response and this finding will be factored into the Phase 2 clinical trial protocol by incorporating the use of hydroxurea to lower peripheral blast burden prior to Actimab-A administration. The Phase 2 trial will enroll 53 patients who will receive 2 fractions of 2.0 µCi/kg of Actimab-A one week apart. In the Phase 1 study, patients who had low peripheral blast burden and who received the 2.0 µCi/kg/fraction of Actimab-A showed a 50% response rate. The Actimab-A Phase 1 poster abstract is viewable through the following page: https://ash.confex.com/ash/2016/webprogram/Paper91235.html. "Actimab-A is showing promising safety and efficacy signals, which gives us great excitement for our current Phase 2 trial," said Sandesh Seth, Executive Chairman of Actinium. "The Notice of Allowance for this patent is a welcome addition to our intellectual property portfolio. We look forward to providing updates on the advancement of our Actimab-A program, specifically the interim analysis that is expected in mid-2017 and the completion of enrollment by the end of 2017."